自発呼吸マウスにおけるバルーンカテーテルを用いた遠隔トリガーLAD閉塞

Executive Industry Relevance

Precise, minimally invasive murine models of myocardial ischemia-reperfusion injury (IRI) are critical for translational cardiovascular drug discovery and mechanistic de-risking. This closed-chest, remotely triggered LAD occlusion protocol enables real-time, noninvasive imaging and reproducible injury induction, supporting predictive confidence in early-stage target validation and intervention assessment. The approach enhances portfolio decision-making by providing robust, quantitative data on acute and chronic cardiac injury responses.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of acute myocardial injury mechanisms under controlled, physiologically relevant conditions.
• Supports functional target validation by correlating intervention timing with tissue response and necrosis markers.
• Facilitates mechanistic de-risking through real-time imaging of ischemia and reperfusion events.

Screening & Assay Development

• Provides a standardized, reproducible platform for evaluating cardioprotective compounds in vivo.
• Allows integration of quantitative imaging endpoints, such as MRI-based area at risk and infarct size.
• Improves assay consistency by minimizing surgical trauma and enabling spontaneous breathing.

Translational & Preclinical Research

• Aligns preclinical models with clinical imaging modalities, supporting translational biomarker development.
• Enables longitudinal assessment of myocardial remodeling and scar maturation post-injury.
• Reduces confounding variables, increasing predictive value for downstream preclinical studies.

Pipeline & Workflow Integration

This method bridges early discovery and preclinical validation by enabling hypothesis-driven testing of cardioprotective strategies with real-time imaging outputs.

• Discovery Biology: Supports hypothesis testing on ischemia-reperfusion mechanisms and intervention timing.
• Screening: Delivers reproducible, quantitative readouts for compound evaluation and prioritization.
• Analytics: Integrates MRI and biomarker measurements for robust statistical comparison of experimental groups.
• Translational Research: Facilitates alignment of preclinical endpoints with clinical imaging standards.
• Enterprise Reuse: Provides a scalable, standardized platform adaptable to diverse cardiovascular research programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac injury models.
• Operational Value: Enhances reproducibility, standardization, and throughput in in vivo cardiovascular studies.
• Strategic Value: Supports informed go/no-go decisions and capital-efficient portfolio advancement.
• Portfolio Impact: Enables risk-adjusted prioritization of cardioprotective targets and interventions.

Implementation Considerations

• Requires expertise in murine cardiovascular surgery and imaging modalities.
• Demands access to MRI or ultrasound infrastructure for real-time data acquisition.
• Necessitates cross-team standardization of surgical and imaging protocols.
• Adaptable to various mouse strains and experimental designs with protocol optimization.
• Potential limitations include technical complexity and imaging resource availability.

Biopharma FAQs